The asthma treatment market size is poised to grow by $ 35.1 billion by 2032 from $ 26.7 Billion in 2022, exhibiting a CAGR of 2.77% during the forecast period 2023-2032.
The main objective of this report is to define, describe, and forecast the global market by types, application, manufacturers, and regions. The report provides detailed information about the major factors (drivers, restraints, opportunities, and industry-specific challenges) influencing the growth of the market. The report aims to strategically analyze the micro markets with respect to individual growth trends, prospects, and contributions to the global market. The report also attempts to forecast the market size of the 5 main regions: North America, Europe, Asia Pacific (APAC), Middle East and Africa (MEA), and Latin America. It strategically profiles the key market players and comprehensively analyzes their core competencies. It also tracks and analyzes competitive developments, such as joint ventures, mergers and acquisitions, new developments, and Research and Development (R&D) activities, in market.
Get a Sample: https://www.precedenceresearch.com/sample/1557
COVID-19 Impact
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the ASTHMA TREATMENT market in 2020.
COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.
The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
Major companies operating in this area
- AstraZeneca
- Teva Pharmaceutical Industries Ltd.
- GlaxoSmithKline plc
- Boehringer Ingelheim International GmbH
- Roche Holding AG / Novartis AG
- Merck & Co., Inc.
- Koninklijke Philips N.V.
- Sanofi-Aventis SA
- MundiPharma.
Market Segmentation
By Medication
- Quick-relief medication
- Long-term control medication
By Route of Administration
- Inhalers
- Prefilled syringes/vials
- Others
By Adjunct Therapy
- LAMA (long-acting muscarinic antagonists)
- LABA (long-acting beta antagonists)
- Others
By Distribution Channel
- Online pharmacies
- Hospital pharmacies
- Retail pharmacies & drug stores
By Geography
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Malaysia
- Philippines
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC
- North Africa
- South Africa
- Rest of the Middle East & Africa
Major highlights of Report:
- Figures related to sales volume, market remuneration, and segmental shares
- Featuring market dynamics
- Growth prospects and expansion graph
- PROCON study of direct & indirect sales channels
- Profiles of prominent traders, dealer, and distributors in the industry
Geographical landscape: North America, Europe, Asia-Pacific, South America, Middle East and Africa
- Industry forecasts based on region and at country level
- Data about sales volume recorded, industry share held, and profit margins amassed
- Overall remuneration and estimated growth rate for each regional market
Major Key Points Covered in Report:
Executive Summary: It includes key trends of the ASTHMA TREATMENT market related to products, applications, and other crucial factors. It also provides analysis of the competitive landscape and CAGR and market size of the ASTHMA TREATMENT market based on production and revenue.
Production and Consumption by Region: It covers all regional markets to which the research study relates. Prices and key players in addition to production and consumption in each regional market are discussed.
Key Players: Here, the report throws light on financial ratios, pricing structure, production cost, gross profit, sales volume, revenue, and gross margin of leading and prominent companies competing in the ASTHMA TREATMENT market.
Market Segments: This part of the report discusses product, application and other segments of the ASTHMA TREATMENT market based on market share, CAGR, market size, and various other factors.
Research Methodology: This section discusses the research methodology and approach used to prepare the report. It covers data triangulation, market breakdown, market size estimation, and research design and/or programs.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Asthma Treatment Market
5.1. COVID-19 Landscape: Asthma Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Asthma Treatment Market, By Medication
8.1. Asthma Treatment Market, by Medication Type, 2021-2027
8.1.1. Quick-relief medication
8.1.1.1. Market Revenue and Forecast (2019-2027)
8.1.2. Long-term control medication
8.1.2.1. Market Revenue and Forecast (2019-2027)
Chapter 9. Global Asthma Treatment Market, By Route of Administration
9.1. Asthma Treatment Market, by Route of Administration, 2021-2027
9.1.1. Inhalers
9.1.1.1. Market Revenue and Forecast (2019-2027)
9.1.2. Prefilled syringes/vials
9.1.2.1. Market Revenue and Forecast (2019-2027)
9.1.3. Others
9.1.3.1. Market Revenue and Forecast (2019-2027)
Chapter 10. Global Asthma Treatment Market, By Adjunct Therapy
10.1. Asthma Treatment Market, by Adjunct Therapy, 2021-2027
10.1.1. LAMA (long-acting muscarinic antagonists)
10.1.1.1. Market Revenue and Forecast (2019-2027)
10.1.2. LABA (long-acting beta antagonists)
10.1.2.1. Market Revenue and Forecast (2019-2027)
10.1.3. Others
10.1.3.1. Market Revenue and Forecast (2019-2027)
Chapter 11. Global Asthma Treatment Market, By Distribution Channel
11.1. Asthma Treatment Market, by Distribution Channel, 2021-2027
11.1.1. Online pharmacies
11.1.1.1. Market Revenue and Forecast (2019-2027)
11.1.2. Hospital pharmacies
11.1.2.1. Market Revenue and Forecast (2019-2027)
11.1.3. Retail pharmacies & drug stores
11.1.3.1. Market Revenue and Forecast (2019-2027)
Chapter 12. Global Asthma Treatment Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Medication (2019-2027)
12.1.2. Market Revenue and Forecast, by Route of Administration (2019-2027)
12.1.3. Market Revenue and Forecast, by Adjunct Therapy (2019-2027)
12.1.4. Market Revenue and Forecast, by Distribution Channel (2019-2027)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Medication (2019-2027)
12.1.5.2. Market Revenue and Forecast, by Route of Administration (2019-2027)
12.1.5.3. Market Revenue and Forecast, by Adjunct Therapy (2019-2027)
12.1.5.4. Market Revenue and Forecast, by Distribution Channel (2019-2027)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Medication (2019-2027)
12.1.6.2. Market Revenue and Forecast, by Route of Administration (2019-2027)
12.1.6.3. Market Revenue and Forecast, by Adjunct Therapy (2019-2027)
12.1.6.4. Market Revenue and Forecast, by Distribution Channel (2019-2027)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Medication (2019-2027)
12.2.2. Market Revenue and Forecast, by Route of Administration (2019-2027)
12.2.3. Market Revenue and Forecast, by Adjunct Therapy (2019-2027)
12.2.4. Market Revenue and Forecast, by Distribution Channel (2019-2027)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Medication (2019-2027)
12.2.5.2. Market Revenue and Forecast, by Route of Administration (2019-2027)
12.2.5.3. Market Revenue and Forecast, by Adjunct Therapy (2019-2027)
12.2.5.4. Market Revenue and Forecast, by Distribution Channel (2019-2027)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Medication (2019-2027)
12.2.6.2. Market Revenue and Forecast, by Route of Administration (2019-2027)
12.2.6.3. Market Revenue and Forecast, by Adjunct Therapy (2019-2027)
12.2.6.4. Market Revenue and Forecast, by Distribution Channel (2019-2027)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Medication (2019-2027)
12.2.7.2. Market Revenue and Forecast, by Route of Administration (2019-2027)
12.2.7.3. Market Revenue and Forecast, by Adjunct Therapy (2019-2027)
12.2.7.4. Market Revenue and Forecast, by Distribution Channel (2019-2027)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Medication (2019-2027)
12.2.8.2. Market Revenue and Forecast, by Route of Administration (2019-2027)
12.2.8.3. Market Revenue and Forecast, by Adjunct Therapy (2019-2027)
12.2.8.4. Market Revenue and Forecast, by Distribution Channel (2019-2027)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Medication (2019-2027)
12.3.2. Market Revenue and Forecast, by Route of Administration (2019-2027)
12.3.3. Market Revenue and Forecast, by Adjunct Therapy (2019-2027)
12.3.4. Market Revenue and Forecast, by Distribution Channel (2019-2027)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Medication (2019-2027)
12.3.5.2. Market Revenue and Forecast, by Route of Administration (2019-2027)
12.3.5.3. Market Revenue and Forecast, by Adjunct Therapy (2019-2027)
12.3.5.4. Market Revenue and Forecast, by Distribution Channel (2019-2027)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Medication (2019-2027)
12.3.6.2. Market Revenue and Forecast, by Route of Administration (2019-2027)
12.3.6.3. Market Revenue and Forecast, by Adjunct Therapy (2019-2027)
12.3.6.4. Market Revenue and Forecast, by Distribution Channel (2019-2027)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Medication (2019-2027)
12.3.7.2. Market Revenue and Forecast, by Route of Administration (2019-2027)
12.3.7.3. Market Revenue and Forecast, by Adjunct Therapy (2019-2027)
12.3.7.4. Market Revenue and Forecast, by Distribution Channel (2019-2027)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Medication (2019-2027)
12.3.8.2. Market Revenue and Forecast, by Route of Administration (2019-2027)
12.3.8.3. Market Revenue and Forecast, by Adjunct Therapy (2019-2027)
12.3.8.4. Market Revenue and Forecast, by Distribution Channel (2019-2027)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Medication (2019-2027)
12.4.2. Market Revenue and Forecast, by Route of Administration (2019-2027)
12.4.3. Market Revenue and Forecast, by Adjunct Therapy (2019-2027)
12.4.4. Market Revenue and Forecast, by Distribution Channel (2019-2027)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Medication (2019-2027)
12.4.5.2. Market Revenue and Forecast, by Route of Administration (2019-2027)
12.4.5.3. Market Revenue and Forecast, by Adjunct Therapy (2019-2027)
12.4.5.4. Market Revenue and Forecast, by Distribution Channel (2019-2027)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Medication (2019-2027)
12.4.6.2. Market Revenue and Forecast, by Route of Administration (2019-2027)
12.4.6.3. Market Revenue and Forecast, by Adjunct Therapy (2019-2027)
12.4.6.4. Market Revenue and Forecast, by Distribution Channel (2019-2027)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Medication (2019-2027)
12.4.7.2. Market Revenue and Forecast, by Route of Administration (2019-2027)
12.4.7.3. Market Revenue and Forecast, by Adjunct Therapy (2019-2027)
12.4.7.4. Market Revenue and Forecast, by Distribution Channel (2019-2027)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Medication (2019-2027)
12.4.8.2. Market Revenue and Forecast, by Route of Administration (2019-2027)
12.4.8.3. Market Revenue and Forecast, by Adjunct Therapy (2019-2027)
12.4.8.4. Market Revenue and Forecast, by Distribution Channel (2019-2027)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Medication (2019-2027)
12.5.2. Market Revenue and Forecast, by Route of Administration (2019-2027)
12.5.3. Market Revenue and Forecast, by Adjunct Therapy (2019-2027)
12.5.4. Market Revenue and Forecast, by Distribution Channel (2019-2027)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Medication (2019-2027)
12.5.5.2. Market Revenue and Forecast, by Route of Administration (2019-2027)
12.5.5.3. Market Revenue and Forecast, by Adjunct Therapy (2019-2027)
12.5.5.4. Market Revenue and Forecast, by Distribution Channel (2019-2027)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Medication (2019-2027)
12.5.6.2. Market Revenue and Forecast, by Route of Administration (2019-2027)
12.5.6.3. Market Revenue and Forecast, by Adjunct Therapy (2019-2027)
12.5.6.4. Market Revenue and Forecast, by Distribution Channel (2019-2027)
Chapter 13. Company Profiles
13.1. AstraZeneca
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Teva Pharmaceutical Industries Ltd.
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. GlaxoSmithKline plc
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Boehringer Ingelheim International GmbH
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Roche Holding AG / Novartis AG
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Merck & Co., Inc.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Koninklijke Philips N.V.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Sanofi-Aventis SA
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. MundiPharma
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.pharma-geek.com
0 Comments